CA2420164A1 - Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk) - Google Patents

Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk) Download PDF

Info

Publication number
CA2420164A1
CA2420164A1 CA002420164A CA2420164A CA2420164A1 CA 2420164 A1 CA2420164 A1 CA 2420164A1 CA 002420164 A CA002420164 A CA 002420164A CA 2420164 A CA2420164 A CA 2420164A CA 2420164 A1 CA2420164 A1 CA 2420164A1
Authority
CA
Canada
Prior art keywords
substituted
group
alkyl
independently selected
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002420164A
Other languages
English (en)
Inventor
David A. Nugiel
Susan V. Di Meo
David J. Carini
Anup Vidwans
Eddy W. Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2420164A1 publication Critical patent/CA2420164A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la synthèse d'une nouvelle classe de indéno [1,2-c]pyrazol-4-ones représentés par la formule (I), qui sont des inhibiteurs puissants de la classe des enzymes connues sous l'appellation de kinases dépendantes des cyclines, qui sont liés aux sous unités catalytiques cdk1-9 et à leurs sous unités régulatrices connues sous l'appellation de cyclines A-H. Cette invention concerne aussi une nouvelle technique de traitement du cancer ou d'autres maladies proliférantes, qui consiste à administrer une quantité thérapeutiquement efficace de l'un de ces composés ou d'un sel de ceux-ci répondant aux normes pharmaceutiques. Dans un autre mode de réalisation de cette invention, on peut traiter le cancer ou d'autres maladie proliférantes en administrant une combinaison thérapeutiquement efficace de l'un de ces composés et d'un ou de plusieurs autres agents anticancéreux ou inhibiteurs de la prolifération connus.
CA002420164A 2000-10-20 2000-10-20 Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk) Abandoned CA2420164A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/028952 WO2002034721A1 (fr) 2000-10-20 2000-10-20 Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk)

Publications (1)

Publication Number Publication Date
CA2420164A1 true CA2420164A1 (fr) 2002-05-02

Family

ID=21741910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002420164A Abandoned CA2420164A1 (fr) 2000-10-20 2000-10-20 Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk)

Country Status (5)

Country Link
EP (1) EP1414804A1 (fr)
JP (1) JP2004524277A (fr)
AU (1) AU2001212168A1 (fr)
CA (1) CA2420164A1 (fr)
WO (1) WO2002034721A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593356B2 (en) * 1999-10-20 2003-07-15 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CA2502979A1 (fr) * 2002-11-06 2004-05-21 Cyclacel Limited Composition pharmaceutique a base de gemcitabine et d'un inhibiteur de cdk
SG173222A1 (en) 2003-04-07 2011-08-29 Agennix Usa Inc Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases, useful for the treatment of alopecia, viral infections and hyperproliferative disorders, a pharmaceutical composition and uses related thereto
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
JP4791975B2 (ja) 2003-12-23 2011-10-12 アジェニックス ユーエスエー インク． サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用
US20080146555A1 (en) * 2004-06-18 2008-06-19 Gpc Biotech, Inc Uses of Kinase Inhibitors and Compositions Thereof
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
BRPI0606455A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
JP5258563B2 (ja) * 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071668B1 (fr) * 1998-04-21 2009-06-03 Bristol-Myers Squibb Pharma Company 5-aminoindeno[1,2-c]pyrazol-4-ones comme agents anticancereux et antiproliferatifs

Also Published As

Publication number Publication date
EP1414804A1 (fr) 2004-05-06
WO2002034721A1 (fr) 2002-05-02
AU2001212168A1 (en) 2002-05-06
JP2004524277A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
US6291504B1 (en) Acylsemicarbazides and their uses
US6849631B2 (en) Semicarbazides and their uses
US6706718B2 (en) 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
CA2420164A1 (fr) Semi-carbazides acyle et utilisations de celles-ci comme inhibiteurs de kinase dependante des cyclines (cdk)
US6407103B2 (en) Indeno [1,2-c] pyrazol-4-ones and their uses
EP1746097B1 (fr) Héterocyles à fusion1,4-dihydropyridineprocédé de préparation, utilisation et compositions de celles-ci
JP5658664B2 (ja) １，２−二置換複素環式化合物
US20080004287A1 (en) Substituted Piperidines that Increase P53 Activity and the Uses Thereof
CA2322204C (fr) 5-aminoindeno(1,2-c)-pyrazol-4-ones agents anticancereux et antiproliferatifs
KR20140041583A (ko) Ｌｒｒｋ2 키나제 활성의 억제제
JP2000514445A (ja) プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物
JP2002537223A (ja) サイクリン依存性キナーゼ阻害剤として有用な６−置換ピラゾロ［３，４−ｄ］ピリミジン−４−オン類
EP3597649A1 (fr) Composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
JP2011525529A (ja) タンパク質キナーゼ阻害剤
JP2012529525A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
ZA200400332B (en) Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
CN102134234B (zh) 吲唑脲类化合物及其制法和药物用途
US20040242869A1 (en) Semicarbazides and their uses
JP6927959B2 (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
EP2488511A1 (fr) Pyrazoles inhibiteurs de phosphatidylinositol 3-kinase
EP2326639A1 (fr) Pyridines substituées et leur utilisation en tant qu'inhibiteurs de la gsk3
KR100888468B1 (ko) 항암활성을 갖는1'-알킬피페리딘-4'-스피로-2-6-(아미도)-2ｈ-벤조피란유도체
JP2022548055A (ja) 置換イミダゾキノキサリン化合物およびその応用
ZA200203492B (en) Heterocyclic substituted pyrazolones.

Legal Events

Date Code Title Description
FZDE Dead